Considering that the Menin inhibitor (revumenib) has shown to suppress NUP98::NSD1 AML cells after 7–10 days, while FLT3-i induces rapid cytotoxicity, we treated AML cells with Menin inhibitor for 10 days followed by addition of FLT3-i for another 3 days. The gene discussed is MEN1; the disease is acute myeloid leukemia.